<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of <z:hpo ids='HP_0002664'>neoplasms</z:hpo> including <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Using immunohistochemical methods, we assessed for HSP90 expression in 412 cases of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, HSP90 was moderately to strongly expressed in <z:hpo ids='HP_0000001'>all</z:hpo> cases of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (5/5, 100%), and in subsets of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (17/28, 61%), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (27/46, 59%), nodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (6/16, 38%), plasma cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (14/39, 36%), small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (3/9, 33%), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (12/38, 32%) and lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005508'>Waldenstrom macroglobulinemia</z:hpo> (3/10, 30%) </plain></SENT>
<SENT sid="3" pm="."><plain>HSP90 was weakly expressed in six of 14 (43%) cases of extranodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of mucosa-associated lymphoid tissue </plain></SENT>
<SENT sid="4" pm="."><plain>In T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, HSP90 was moderately to strongly expressed in subsets of anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (14/24, 58%; 9/12 ALK+ and 5/12 ALK-), precursor-T-cell lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (20/65, 31%), unspecified peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (8/43, 23%) and angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2/17, 12%) </plain></SENT>
<SENT sid="5" pm="."><plain>HSP90 was weakly expressed in seven of 58 (12%) cases of <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that HSP90 is commonly expressed in a subset of many types of B- and T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that many <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types are suitable targets for modulation of HSP90 activity, and that HSP90 inhibitors are a potential investigational therapy for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
</text></document>